{"hands_on_practices": [{"introduction": "In the acute setting, differentiating immune thrombotic thrombocytopenic purpura (TTP) from other thrombotic microangiopathies is a critical challenge where treatment cannot await definitive test results. Clinical prediction tools like the PLASMIC score are essential for rapidly stratifying risk and guiding the decision to initiate emergent therapy. This exercise hones your ability to apply diagnostic test characteristics derived from clinical data to determine a patient's post-test probability of disease, a cornerstone of evidence-based clinical reasoning. [@problem_id:4904881]", "problem": "A hospital maintains a prospective registry of adults presenting with microangiopathic hemolytic anemia (MAHA) and severe thrombocytopenia defined as platelets less than $30 \\times 10^{9}$ per liter. Immune-mediated thrombotic thrombocytopenic purpura (TTP) is defined by severe A Disintegrin And Metalloprotease with ThromboSpondin type $1$ motif, member $13$ (ADAMTS$13$) activity less than $10\\%$. The following is observed in a cohort of $N = 200$ consecutive patients meeting the registry entry criteria:\n- $70$ patients had immune-mediated TTP confirmed by ADAMTS$13$ activity less than $10\\%$.\n- The Platelets, combined hemolysis variables, no Active cancer, no Solid organ or stem cell transplant, Mean corpuscular volume less than $90$ femtoliters, International normalized ratio less than $1.5$, and Creatinine less than $2.0$ milligrams per deciliter (PLASMIC) score was used as a clinical test, where a threshold of PLASMIC score greater than or equal to $6$ is considered a positive test.\n- Among the $70$ TTP cases, $63$ had PLASMIC score greater than or equal to $6$.\n- Among the $130$ non-TTP cases, $26$ had PLASMIC score greater than or equal to $6$.\n\nA new patient presents with MAHA and platelets less than $30 \\times 10^{9}$ per liter and has a PLASMIC score of $6$.\n\nUsing only fundamental definitions of pretest probability (as the disease probability before considering the test result within the target population) and probability updating from test performance, and taking the registry population as the reference class for pretest risk, compute the post-test probability that this new patient has immune-mediated TTP after observing a PLASMIC score of $6$ (treat this as a positive test at the stated threshold). Express your final answer as a single fraction in simplest terms. Do not use a percentage sign. Report only the post-test probability.", "solution": "The problem is assessed to be valid. It is self-contained, scientifically grounded in medical diagnostics and probability theory, and mathematically consistent. All necessary data are provided to compute the requested quantity.\n\nThe objective is to calculate the post-test probability of a patient having immune-mediated thrombotic thrombocytopenic purpura (TTP) given a positive test result. This is a classic application of conditional probability, often framed using Bayes' theorem.\n\nLet us define the following events:\n- $D$: The event that a patient has immune-mediated TTP.\n- $D^c$: The event that a patient does not have TTP.\n- $T$: The event that a patient has a positive test result, defined as a PLASMIC score greater than or equal to $6$.\n- $T^c$: The event that a patient has a negative test result, defined as a PLASMIC score less than $6$.\n\nThe quantity we need to compute is the conditional probability $P(D|T)$, which represents the probability of having the disease $D$ given that a positive test result $T$ has been observed.\n\nFrom the problem statement, we extract the following data for the cohort of $N = 200$ patients:\n- The total number of patients with TTP is $70$. This corresponds to the count of event $D$, so $N(D) = 70$.\n- The total number of patients without TTP is $130$. This corresponds to the count of event $D^c$, so $N(D^c) = 130$. We can verify that $N(D) + N(D^c) = 70 + 130 = 200 = N$.\n- The number of TTP cases with a PLASMIC score $\\ge 6$ (a positive test) is $63$. This corresponds to the count of the intersection of events $D$ and $T$, so $N(D \\cap T) = 63$. These are the True Positives (TP).\n- The number of non-TTP cases with a PLASMIC score $\\ge 6$ is $26$. This corresponds to the count of the intersection of events $D^c$ and $T$, so $N(D^c \\cap T) = 26$. These are the False Positives (FP).\n\nThe fundamental definition of conditional probability is $P(A|B) = \\frac{P(A \\cap B)}{P(B)}$. In our context, this is:\n$$\nP(D|T) = \\frac{P(D \\cap T)}{P(T)}\n$$\nThe probabilities can be calculated from the counts in the reference population:\n- The probability of a patient having both TTP and a positive test is $P(D \\cap T) = \\frac{N(D \\cap T)}{N} = \\frac{63}{200}$.\n- The probability of a patient having a positive test, $P(T)$, can be found by considering all patients who tested positive, regardless of their disease status. The total number of patients with a positive test is the sum of True Positives and False Positives:\n$$\nN(T) = N(D \\cap T) + N(D^c \\cap T) = 63 + 26 = 89\n$$\nTherefore, the probability of a randomly selected patient from this cohort having a positive test is:\n$$\nP(T) = \\frac{N(T)}{N} = \\frac{89}{200}\n$$\nNow we can compute the post-test probability $P(D|T)$:\n$$\nP(D|T) = \\frac{P(D \\cap T)}{P(T)} = \\frac{\\frac{63}{200}}{\\frac{89}{200}} = \\frac{63}{89}\n$$\nAlternatively, and perhaps more intuitively, we can restrict our sample space to only those patients who had a positive test. The total number of such patients is $N(T) = 89$. Within this group of $89$ patients, the number who actually have TTP is $N(D \\cap T) = 63$. Thus, the probability that a patient has TTP, given that they are in this group (i.e., they tested positive), is the ratio of these counts:\n$$\nP(D|T) = \\frac{\\text{Number of patients with disease and positive test}}{\\text{Total number of patients with positive test}} = \\frac{N(D \\cap T)}{N(T)} = \\frac{63}{89}\n$$\nBoth approaches yield the same result. The problem requires the answer as a fraction in simplest terms. To check if $\\frac{63}{89}$ can be simplified, we find the prime factors of the numerator and denominator.\nThe prime factorization of the numerator is $63 = 3^2 \\times 7$.\nThe denominator, $89$, is not divisible by $3$ (since the sum of its digits, $8+9=17$, is not divisible by $3$) nor by $7$ (since $89 = 12 \\times 7 + 5$). In fact, $89$ is a prime number.\nTherefore, the fraction $\\frac{63}{89}$ is in its simplest form.\n\nThe pretest probability of TTP in this population was $P(D) = \\frac{70}{200} = \\frac{7}{20} = 0.35$. After observing a positive test result, the updated probability (post-test probability) is $\\frac{63}{89} \\approx 0.7079$, which demonstrates a significant increase in the likelihood of disease, as expected from a clinically useful test.", "answer": "$$\\boxed{\\frac{63}{89}}$$", "id": "4904881"}, {"introduction": "Therapeutic plasma exchange (TPE) is the cornerstone of treatment for immune TTP, working by removing pathogenic autoantibodies and replenishing functional A Disintegrin and Metalloprotease with Thrombospondin type 1 motif, member 13 (ADAMTS13). The effectiveness of this life-saving intervention depends on prescribing the correct \"dose,\" which is the volume of plasma exchanged. This practice will guide you through the essential calculation of a patient-specific TPE volume, translating basic physiological parameters like weight and hematocrit into a precise therapeutic order. [@problem_id:4905037]", "problem": "A patient with thrombotic thrombocytopenic purpura (TTP) is initiated on daily therapeutic plasma exchange, a core intervention in thrombotic microangiopathies such as TTP and hemolytic uremic syndrome (HUS). Use the following well-tested clinical facts as the fundamental base: the total blood volume can be approximated by $0.07 \\times \\text{weight}$ in liters, the hematocrit (Hct) is the fraction of blood volume occupied by red blood cells so that the plasma volume equals the blood volume multiplied by $(1 - \\text{Hct})$, and severe immune-mediated TTP is treated with daily exchange of $1.5$ plasma volumes to rapidly remove inhibitory autoantibodies to A Disintegrin And Metalloprotease with Thrombospondin type 1 motif, member 13 (ADAMTS13) and replenish functional enzyme.\n\nFor a $70$ kg patient with hematocrit $0.40$, compute the daily plasma volume to be exchanged, assuming one session exchanges $1.5$ times the patientâ€™s plasma volume. Express the final volume in liters and round your answer to four significant figures. Provide a single numerical answer.", "solution": "The problem requires the calculation of the daily plasma exchange volume for a patient with thrombotic thrombocytopenic purpura (TTP). The solution is derived by systematically applying the provided formulas and data.\n\nLet $W$ be the patient's weight in kilograms (kg), Hct be the hematocrit (expressed as a decimal fraction), $V_B$ be the total blood volume in liters (L), $V_P$ be the plasma volume in liters (L), and $V_E$ be the exchange volume in liters (L).\n\nThe given values are:\n- Patient's weight, $W = 70$ kg.\n- Patient's hematocrit, Hct $= 0.40$.\n\nThe problem provides the following relationships:\n$1$. The total blood volume is given by the formula:\n$$V_B = 0.07 \\times W$$\n\n$2$. The plasma volume is a fraction of the total blood volume, determined by the hematocrit:\n$$V_P = V_B \\times (1 - \\text{Hct})$$\n\n$3$. The therapeutic exchange volume is specified as $1.5$ times the patient's plasma volume:\n$$V_E = 1.5 \\times V_P$$\n\nThe calculation proceeds in three sequential steps.\n\nFirst, we calculate the patient's total blood volume, $V_B$, using the given weight, $W = 70$ kg.\n$$V_B = 0.07 \\times 70 \\text{ L} = 4.9 \\text{ L}$$\n\nSecond, we determine the patient's total plasma volume, $V_P$, using the calculated blood volume, $V_B = 4.9$ L, and the given hematocrit, Hct $= 0.40$.\n$$V_P = 4.9 \\text{ L} \\times (1 - 0.40)$$\n$$V_P = 4.9 \\text{ L} \\times 0.60$$\n$$V_P = 2.94 \\text{ L}$$\n\nThird, we compute the required daily plasma exchange volume, $V_E$. The procedure calls for an exchange of $1.5$ plasma volumes.\n$$V_E = 1.5 \\times V_P$$\nSubstituting the calculated plasma volume, $V_P = 2.94$ L:\n$$V_E = 1.5 \\times 2.94 \\text{ L}$$\n$$V_E = 4.41 \\text{ L}$$\n\nThe problem specifies that the final answer should be rounded to four significant figures. The calculated value is exactly $4.41$. To express this value with four significant figures, we include a trailing zero, which is significant in this context.\n$$V_E = 4.410 \\text{ L}$$\nThis value represents the volume of plasma to be exchanged daily.", "answer": "$$\\boxed{4.410}$$", "id": "4905037"}, {"introduction": "Modern TTP management is enhanced by targeted agents like caplacizumab, which rapidly inhibits the formation of microthrombi by blocking the interaction between ultra-large von Willebrand factor multimers and platelets. Unlike many traditional drugs, its dosing follows a complex, event-based schedule tied to plasma exchange sessions and a fixed maintenance period. This problem simulates a realistic treatment course to build proficiency in applying such protocols, a skill vital for ensuring both therapeutic efficacy and patient safety with novel biologics. [@problem_id:4904888]", "problem": "A patient with thrombotic thrombocytopenic purpura (TTP) presents with severe thrombocytopenia and hemolysis consistent with a deficiency of A Disintegrin And Metalloprotease with Thrombospondin type 1 motif, member 13 (ADAMTS13), leading to accumulation of ultra-large von Willebrand factor (vWF) multimers and disseminated microvascular thrombosis. Caplacizumab, an anti-von Willebrand factor nanobody, is initiated concomitantly with plasma exchange (PEX) and immunosuppression. You are asked to calculate the total amount of caplacizumab administered over the induction and early maintenance period for this new episode, based on the following widely accepted dosing regimen and clinical schedule.\n\nWell-tested dosing facts to use:\n- Caplacizumab is given as a fixed-dose initial intravenous loading of $10\\ \\mathrm{mg}$ before the first plasma exchange (PEX) session, followed by a $10\\ \\mathrm{mg}$ subcutaneous dose after completion of each PEX session.\n- After PEX is stopped, caplacizumab is continued as a daily $10\\ \\mathrm{mg}$ subcutaneous dose for at least $30$ consecutive days.\n\nClinical schedule for this episode:\n- Hospital day $1$: $1$ PEX session (morning). Caplacizumab $10\\ \\mathrm{mg}$ intravenous loading is given before this first PEX; then a $10\\ \\mathrm{mg}$ subcutaneous dose is given after completion of the session.\n- Hospital day $2$: $2$ PEX sessions (morning and late afternoon). A $10\\ \\mathrm{mg}$ subcutaneous dose is given after each session.\n- Hospital day $3$: $1$ PEX session; a $10\\ \\mathrm{mg}$ subcutaneous dose is given after the session.\n- Hospital day $4$: $0$ PEX sessions due to machine malfunction; no caplacizumab is administered on this day because dosing during the PEX phase occurs after completed sessions.\n- Hospital day $5$: $1$ PEX session; a $10\\ \\mathrm{mg}$ subcutaneous dose is given after the session.\n- Hospital day $6$: $1$ PEX session; a $10\\ \\mathrm{mg}$ subcutaneous dose is given after the session.\n- Hospital day $7$: $1$ PEX session; a $10\\ \\mathrm{mg}$ subcutaneous dose is given after the session. PEX is then discontinued after day $7$.\n- Hospital days $8$ through $37$: $30$ consecutive days of post-PEX maintenance, each with a $10\\ \\mathrm{mg}$ subcutaneous dose daily, with no missed doses.\n\nUsing these facts and schedule, compute the total amount of caplacizumab administered over hospital days $1$ through $37$. Express your final answer in $\\mathrm{mg}$. No rounding is required; report the exact value.", "solution": "To determine the total amount of caplacizumab administered, we must sum the amounts given during three distinct periods as defined by the dosing regimen and clinical schedule: the initial loading dose, the doses administered during the plasma exchange (PEX) phase, and the doses administered during the post-PEX maintenance phase.\n\nLet $M_{total}$ be the total amount of caplacizumab administered, in milligrams. We can express this as the sum of the amounts from each phase:\n$$M_{total} = M_{loading} + M_{PEX} + M_{maintenance}$$\nwhere $M_{loading}$ is the initial loading dose, $M_{PEX}$ is the total amount given during the PEX phase, and $M_{maintenance}$ is the total amount given during the post-PEX maintenance phase.\n\n1.  **Calculation of the Initial Loading Dose ($M_{loading}$)**\n    The dosing instructions state: \"Caplacizumab is given as a fixed-dose initial intravenous loading of $10\\ \\mathrm{mg}$ before the first plasma exchange (PEX) session.\" This is a single, one-time dose administered on hospital day $1$.\n    $$M_{loading} = 10$$\n\n2.  **Calculation of the Doses During the PEX Phase ($M_{PEX}$)**\n    The rule for this phase is: \"a $10\\ \\mathrm{mg}$ subcutaneous dose after completion of each PEX session.\" The PEX phase spans from hospital day $1$ to day $7$. We must sum the number of PEX sessions completed during this period. Let $N_{PEX,d}$ be the number of PEX sessions on day $d$. The total number of sessions, $N_{PEX,total}$, is:\n    $$N_{PEX,total} = N_{PEX,1} + N_{PEX,2} + N_{PEX,3} + N_{PEX,4} + N_{PEX,5} + N_{PEX,6} + N_{PEX,7}$$\n    According to the provided clinical schedule:\n    - Day $1$: $N_{PEX,1} = 1$ session\n    - Day $2$: $N_{PEX,2} = 2$ sessions\n    - Day $3$: $N_{PEX,3} = 1$ session\n    - Day $4$: $N_{PEX,4} = 0$ sessions\n    - Day $5$: $N_{PEX,5} = 1$ session\n    - Day $6$: $N_{PEX,6} = 1$ session\n    - Day $7$: $N_{PEX,7} = 1$ session\n    \n    Summing these values:\n    $$N_{PEX,total} = 1 + 2 + 1 + 0 + 1 + 1 + 1 = 7$$\n    A dose of $10\\ \\mathrm{mg}$ is administered after each of these $7$ sessions. Therefore, the total amount given during the PEX phase is:\n    $$M_{PEX} = N_{PEX,total} \\times 10 = 7 \\times 10 = 70$$\n\n3.  **Calculation of the Doses During the Maintenance Phase ($M_{maintenance}$)**\n    The instructions for this phase are: \"After PEX is stopped, caplacizumab is continued as a daily $10\\ \\mathrm{mg}$ subcutaneous dose for at least $30$ consecutive days.\" The schedule specifies that PEX is discontinued after day $7$, and the maintenance phase runs from \"Hospital days $8$ through $37$,\" which is explicitly stated to be \"$30$ consecutive days.\" The number of days, $N_{maint}$, is $30$.\n    On each of these $30$ days, a $10\\ \\mathrm{mg}$ dose is administered. The total amount is:\n    $$M_{maintenance} = N_{maint} \\times 10 = 30 \\times 10 = 300$$\n\n4.  **Calculation of the Total Amount ($M_{total}$)**\n    Finally, we sum the amounts from all three phases to find the total amount of caplacizumab administered during the period from day $1$ to day $37$:\n    $$M_{total} = M_{loading} + M_{PEX} + M_{maintenance}$$\n    $$M_{total} = 10 + 70 + 300 = 380$$\n    The total amount of caplacizumab administered is $380\\ \\mathrm{mg}$.", "answer": "$$\\boxed{380}$$", "id": "4904888"}]}